Sponsor: Rubicon Genomics
Recording Date: 2/19/2014
Recording Time: 1 hour
Omicia is hiring Bioinformaticists who will drive the design of our market leading annotation and analysis pipelines. You will collaborate with other scientists, developers and users to develop novel techniques for analyzing genomic data with the goal of developing actionable insight on genomic data. We are looking for eager and hands-on candidates who can work effectively in a dynamic startup environment, and want to help shape the future of personalized medicine.
- Design analysis pipelines for large-scale genome data analysis
- Develop statistical algorithms to identify patterns in genome data
- Develop analysis methods and visualizations to help users interpret data
- Experience developing software in Python and Perl
- Significant experience developing software for deployment on Linux/Unix
- Experience with data management systems such as PostgreSQL and MySQL
- Team player with excellent communication and interpersonal skills
- PhD with strong background in computational biology or related field
Please submit your resume and cover letter to firstname.lastname@example.org.
Omicia is unlocking the potential of personalized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from personal genome sequences, to improve disease management and medical outcomes.
Researchers and clinical diagnostic organizations use our solutions to analyze and identify the genetic basis of a variety of conditions, including childhood disease, cancer and cardiovascular disease. Opal, the leading platform for fast, accurate and flexible genome analysis, enables clinicians, researchers and bioinformaticians alike to derive clinically relevant insights from genomic data. VAAST, our robust novel disease gene finder and variant scoring algorithm, is in use at more than 200 academic and clinical institutions including the NIH, Stanford University, University of Cambridge, Seattle Children's Research Institute, Institut Pasteur, University of Maryland Institute for Genome Sciences, and UCSF.